• Robert S Rosenson, Steven Baker, Maciej Banach, Kenneth M Borow, Lynne T Braun, Eric Bruckert, Liam R Brunham, Alberico L Catapano, Marshall B Elam, ManciniG B JohnGBJDepartment of Medicine, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada., Patrick M Moriarty, Pamela B Morris, Paul Muntner, Kausik K Ray, Erik S Stroes, Beth A Taylor, Valerie H Taylor, Gerald F Watts, and Paul D Thompson.
• Department of Medicine, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: robert.rosenson@mssm.edu.
• J. Am. Coll. Cardiol. 2017 Sep 5; 70 (10): 1290-1301.

AbstractStatins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.Copyright © 2017 American College of Cardiology Foundation. All rights reserved.

20 keywords...

hide…